These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23079301)

  • 1. Setting priorities in and for end-of-life care: challenges in the application of economic evaluation.
    Normand C
    Health Econ Policy Law; 2012 Oct; 7(4):431-9. PubMed ID: 23079301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring outcomes in palliative care: limitations of QALYs and the road to PalYs.
    Normand C
    J Pain Symptom Manage; 2009 Jul; 38(1):27-31. PubMed ID: 19615624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes measurement: health state preferences and economic evaluation.
    Oldridge NB
    Assist Technol; 1996; 8(2):94-102. PubMed ID: 10163933
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health services research on end-of-life care.
    Costantini M; Beccaro M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):190-4. PubMed ID: 19512931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health system and equity perspectives in health technology assessment.
    Hanvoravongchai P
    J Med Assoc Thai; 2008 Jun; 91 Suppl 2():S74-87. PubMed ID: 19253490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Palliative care: an example of Comparative Effectiveness Research?].
    Schmacke N
    Z Evid Fortbild Qual Gesundhwes; 2012; 106(7):484-91. PubMed ID: 22981024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bridging the gap between methods research and the needs of policy makers: a review of the research priorities of the National Institute for Health and Clinical Excellence.
    Longworth L; Sculpher MJ; Bojke L; Tosh JC
    Int J Technol Assess Health Care; 2011 Apr; 27(2):180-7. PubMed ID: 21447260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modelling in the economic evaluation of health care: selecting the appropriate approach.
    Barton P; Bryan S; Robinson S
    J Health Serv Res Policy; 2004 Apr; 9(2):110-8. PubMed ID: 15099459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 10. Health technology assessment: research trends and future priorities in Europe.
    Nielsen CP; Funch TM; Kristensen FB
    J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation and the postponement of health care costs.
    van Baal PH; Feenstra TL; Polder JJ; Hoogenveen RT; Brouwer WB
    Health Econ; 2011 Apr; 20(4):432-45. PubMed ID: 21210494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care costs in end-of-life and palliative care: the quest for ethical reform.
    Jennings B; Morrissey MB
    J Soc Work End Life Palliat Care; 2011; 7(4):300-17. PubMed ID: 22150176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Supporting lay carers in end of life care: current gaps and future priorities.
    Grande G; Stajduhar K; Aoun S; Toye C; Funk L; Addington-Hall J; Payne S; Todd C
    Palliat Med; 2009 Jun; 23(4):339-44. PubMed ID: 19304804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Family pediatrics: report of the Task Force on the Family.
    Schor EL;
    Pediatrics; 2003 Jun; 111(6 Pt 2):1541-71. PubMed ID: 12777595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost of end-of-life care: a new efficiency measure falls short of AHA/ACC standards.
    Neuberg GW
    Circ Cardiovasc Qual Outcomes; 2009 Mar; 2(2):127-33. PubMed ID: 20031825
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective value-based assessment of new health care technologies and practices.
    Girod CS; Axene DV
    Manag Care; 2000 Aug; 9(8):38-40, 43-7. PubMed ID: 11186514
    [No Abstract]   [Full Text] [Related]  

  • 17. ['Medical technology assessment'; more than just efficacy].
    Buskens E
    Ned Tijdschr Geneeskd; 2000 Mar; 144(13):622-6. PubMed ID: 10761552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug utilization and medication costs at the end of life.
    Pont L; Jansen K; Schaufel MA; Haugen DF; Ruths S
    Expert Rev Pharmacoecon Outcomes Res; 2016; 16(2):237-43. PubMed ID: 26919437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analysis and quality adjusted life years.
    Joish VN; Oderda GM
    J Pain Palliat Care Pharmacother; 2005; 19(1):57-61. PubMed ID: 15814516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of medical methods--can we rely on cost-benefit-analysis?].
    Kristiansen IS; Stavem K; Linnestad K; Pedersen KM
    Tidsskr Nor Laegeforen; 2003 Mar; 123(5):657-60. PubMed ID: 12683199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.